Health plan retention and pharmacy costs of newly diagnosed patients with chronic kidney disease in a managed care population

American Health and Drug Benefits

Volumn 2, Issue 7, 2009, Pages 283-290

  Kubacki, Maureen ^a   Carter, Chureen ^a   Herrera, Alan D L ^a   Wang, Jim ^a   Lopez, Janice M ^a   Piech, Catherine T ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE DURATION; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL PATIENT; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOME ASSESSMENT; PHARMACY; TREATMENT DURATION;

EID: 77953443057     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. National Kidney Foundation. The facts about chronic kidney disease (CKD). www.kidney.org/kidneydisease/ckd/index.cfm#facts. Accessed June 28, 2008.
2. The American Society of Nephrology. Facts and Statistics. www.asn-online.org/ facts-and-statistics/faq.aspx. Accessed June 28, 2008.
3. Centers for Medicare & Medicaid Services. Medicare Coverage of Kidney Dialysis and Kidney Transplant Services. May 2008. www.medicare.gov/ Publications/ Pubs/pdf/10128.pdf. Accessed June 28, 2008.
4. Sullivan S. Employer challenges with the chronic kidney disease population. J Manag Care Pharm. 2007;13(9 suppl D):S19-S21.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
6. Kamal-Bahl SJ, Pantely S, Pyenson B, Alexander CM. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease. Prev Chronic Disease. 2006;3:A83. Epub 2006 Jun 15.
7. Rasu RS, Crawford T, Manley HJ, Balkrishnan R. Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review. Expert Opin Pharmacother. 2007;8:2543-2551.
8. London R, Solis A, Goldberg GA, et al. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manag Care Pharm. 2003;9:248-255.
9. Robbins JD, Kim JJ, Zdon G, et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. J Manag Care Pharm. 2003;9:238-247.
10. Chronic kidney disease: stating the managed care case for early treatment. Discussion and consensus of presentations of economic analyses, managed care organization case studies, and opportunities for intervention in a managed care setting. May 3-5, 2001, Chicago, Illinois. Am J Manag Care. 2002;8(4 suppl):S112-S120.
11. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007;13(3 suppl):S1-S9.
12. Wright A. Preparing MCOs to manage chronic kidney disease. Manag Care. 2003;Spec No:13-6; discussion 17-20.
13. IMS Health. PharMetrics patient-centric database. Watertown, MA; 2008.
14. Ingenix. Symmetry episode treatment groups: measuring health care with meaningful episodes of care. 2007. www.ingenix.com/content/attachments/Symmetry ETG-WhitePaper.pdf. Accessed June 27, 2008.
15. Smith DH, Gullion CM, Nichols G, et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004;15:1300-1306.
16. Geisel J. House panel approves renal care cost-shift. Business Insurance. July 30, 2007. www.businessinsurance.com/article/20070730/NEWS/ 200010770. Accessed October 16, 2008.